Long-Term Improvement in Patients with moderate to severe atopic Dermatitis treated with Tralokinumab: An ECZTEND Interim Analysis

被引：0

作者：

Beissert, Stefan ^{[1
]}

Blauvelt, Andrew ^{[2
]}

Lacour, Jean-Philippe ^{[3
]}

Toth, Darryl ^{[4
]}

Laquer, Vivian ^{[5
]}

Herranz, Pedro ^{[6
]}

Pink, Andrew ^{[7
]}

Peris, Ketty ^{[8
]}

Fangel, Stine ^{[9
]}

Saeki, Hidehisa ^{[10
]}

Wollenberg, Andreas ^{[11
]}

机构：

[1] Univ Klinikum Carl Gustav Carus, Klin & Poliklin Dermatol, Dresden, Germany

[2] Oregon Med Res Ctr, Portland, OR USA

[3] Univ Hosp Nice Cote Azur, Dept Dermatol, Nice, France

[4] Prob Med Res, Windsor, ON, Canada

[5] First OC Dermatol, Fountain Valley, CA USA

[6] La Paz Univ Hosp, Madrid, Spain

[7] Guys & St Thomas Hosp, St Johns Inst Dermatol, London, England

[8] Univ Cattolica Sacro Cuore, Inst Dermatol, Rom, Italy

[9] LEO Pharma AS, Ballerup, Denmark

[10] Nippon Med Sch, Dept Dermatol, Tokyo, Japan

[11] Ludwig Maximilians Univ Munchen, Klinikum LMU Munchen, Klin & Poliklin Dermatol & Allergol, Munich, Germany

来源：

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2022年 / 20卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P049

引用

页码：29 / 30

页数：2

共 50 条

[1] Long-term improvements observed in tralokinumab-treated patients with moderate-to-severe atopic dermatitis: an ECZTEND interim analysis
Blauvelt, A.
Lacour, J. -P.
Toth, D.
Laquer, V.
Beissert, S.
Wollenberg, A.
Herranz, P.
Pink, A.
Peris, K.
Fangel, S.
Saeki, H.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E112 - E113
[2] Long-term safety and efficacy of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: an interim analysis of ECZTEND
Simpson, Eric
Paller, Amy
Wollenberg, Andreas
Bewley, Anthony
Cork, Michael
Hong, Chih-Ho
Soong, Weily
Almgren, Peter
Carlsson, Anna
Blauvelt, Andrew
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB190 - AB190
[3] Long-term safety and efficacy of tralokinumab in more than 1400 moderate-to-severe atopic dermatitis patients treated for up to 42 months: An interim analysis of ECZTEND
Blauvelt, Andrew
Langley, Richard
Simpson, Eric
Warren, Richard B.
Costanzo, Antonio
Saeki, Hidehisa
Toth, Darryl
Tauber, Marie
Pinter, Andreas
Ameen, Mahreen
Reich, Kristian
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB181 - AB181
[4] Long-term safety and efficacy of tralokinumab in more than 1400 patients with moderate-to-severe atopic dermatitis treated for up to 42 months: an interim analysis of ECZTEND
Blauvelt, Andrew
Langley, Richard
Simpson, Eric
Warren, Richard B.
Costanzo, Antonio
Saeki, Hidehisa
Fangel, Stine
Lassota, Nathan
Carlsson, Anna
Toth, Darryl
Tauber, Marie
Pinter, Andreas
Ameen, Mahreen
Reich, Kristian
BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E92 - E93
[5] Long-term tralokinumab therapy in moderate to severe atopic dermatitis
Lorenz, Judith
AKTUELLE DERMATOLOGIE, 2023, 49 (03) : 91 - 91
[6] Long-Term Safety, Efficacy, and Adherence of Tralokinumab for the Treatment of Patients with moderate to severe atopic Dermatitis over a Period of up to 3 Years: Interim Analysis of ECZTEND, a Phase III Long-Term Extension Study
Wollenberg, Andreas
Blauvelt, Andrew
Lacour, Jean-Philippe
Toth, Darryl
Laquer, Vivian
Herranz, Pedro
Pink, Andrew
Peris, Ketty
Saeki, Hidehisa
Beissert, Stefan
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 19 - 20
[7] COVID-19 in tralokinumab-treated patients with moderate-to-severe atopic dermatitis: case series from the ECZTEND long-term extension trial
Blauvelt, A.
Pink, A.
Worm, M.
Langley, R.
Costanzo, A.
Gjerum, L.
Jorgensen, E.
Corriveau, J.
Guttman-Yassky, E.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E109 - E110
[8] Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial
Blauvelt, Andrew
Langley, Richard G.
Lacour, Jean-Philippe
Toth, Darryl
Laquer, Vivian
Beissert, Stefan
Wollenberg, Andreas
Herranz, Pedro
Pink, Andrew E.
Peris, Ketty
Fangel, Stine
Gjerum, Le
Corriveau, Joshua
Saeki, Hidehisa
Warren, Richard B.
Simpson, Eric
Reich, Kristian
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (04) : 815 - 824
[9] Long-term efficacy, safety, and adherence to tralokinumab treatment in moderate-to-severe atopic dermatitis for up to 3 years: Interim readout of ECZTEND, a phase 3, long-term extension trial
Blauvelt, Andrew
Lacour, Jean-Philippe
Toth, Darryl
Laquer, Vivian
Beissert, Stefan
Wollenberg, Andreas
Herranz, Pedro
Pink, Andrew
Peris, Ketty
Saeki, Hidehisa
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB159 - AB159
[10] LONG-TERM EFFICACY OF TRALOKINUMAB IN ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
Wollenberg, Andreas
Paller, Amy S.
Bewley, Anthony
Cork, Michael
Hong, Chih-Ho
Soong, Weily
Oland, Christian Bjerregard
Taveira, Christian Moreira
Gjerum, Le
Blauvelt, Andrew
ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 54 - 54

← 1 2 3 4 5 →